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Abstract
Objective: A genomic region near the CDKN2A locus, encoding p16
INK4a, has been associated to type 2 diabetes and
atherosclerotic vascular disease, conditions in which inflammation plays an important role. Recently, we found that
deficiency of p16
INK4a results in decreased inflammatory signaling in murine macrophages and that p16
INK4a influences the
phenotype of human adipose tissue macrophages. Therefore, we investigated the influence of immune cell p16
INK4a on
glucose tolerance and atherosclerosis in mice.
Methods and Results: Bone marrow p16
INK4a-deficiency in C57Bl6 mice did not influence high fat diet-induced obesity nor
plasma glucose and lipid levels. Glucose tolerance tests showed no alterations in high fat diet-induced glucose intolerance.
While bone marrow p16
INK4a-deficiency did not affect the gene expression profile of adipose tissue, hepatic expression of
the alternative markers Chi3l3, Mgl2 and IL10 was increased and the induction of pro-inflammatory Nos2 was restrained on
the high fat diet. Bone marrow p16
INK4a-deficiency in low density lipoprotein receptor-deficient mice did not affect western
diet-induced atherosclerotic plaque size or morphology. In line, plasma lipid levels remained unaffected and p16
INK4a-
deficient macrophages displayed equal cholesterol uptake and efflux compared to wild type macrophages.
Conclusion: Bone marrow p16
INK4a-deficiency does not affect plasma lipids, obesity, glucose tolerance or atherosclerosis in
mice.
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Introduction
Genome-wide association studies (GWAS) identified a linkage
disequilibrium between several single nucleotide polymorphisms
(SNPs) in non-coding regions of the human chromosome 9p21 and
the risk for type 2 diabetes [1] and atherosclerotic vascular disease
[2]. The coding sequences closest to this locus include CDKN2A
(coding for the cyclin-dependent kinase [CDK] inhibitors
p16
INK4a and its alternative reading frame transcript variant
p14
ARF), CDKN2B (coding for the CDK inhibitor p15
INK4b) [3],
and ANRIL, an antisense non-coding RNA [4] partially
overlapping the high risk interval [5]. The gene products of the
CDKN2A/B locus are known tumor suppressors which function
as cell cycle inhibitors [3]. ANRIL is implicated in CDKN2A [6]
and CDKN2B [7] silencing and ANRIL expression strongly
correlates with the identified risk-associated SNPs [8]. In line,
several of these SNPs correlate with p16
INK4a and p15
INK4b
expression levels in peripheral blood cells [8], suggesting a role for
the gene products of the CDKN2A/B locus in the found genetic
association.
Interestingly, deletion of a region of mouse chromosome 4,
orthologous to the human 9p21 risk interval, was shown to
increase body weight, further linking this region with obesity and
metabolic risk [9]. Atherosclerosis formation induced by a cholate-
containing diet was not affected. However, these mice were not
crossed in an atherosclerosis-prone genetic background [9],
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rosis. Using a series of subcongenic mouse strains, Kuo et al.
recently linked this genomic region to decreased p16
INK4a and
p19
ARF (the murine variant of p14
ARF) gene expression in
macrophages and monocytes and to atherosclerosis formation in
the atherosclerosis-prone low density lipoprotein receptor-deficient
(ldlr
2/2) background [10]. Additionally, p19
ARF-deficiency has
been shown to be pro-atherogenic in an apolipoprotein E-deficient
(apoe
2/2) background [11]. Although the latter study did not
clearly identify the cell type involved, the study of Kuo et al. showed
that bone marrow-specific reduced CDKN2A expression (including
p16
INK4a and p19
ARF) is required and sufficient to accelerate
atherosclerosis formation in ldlr
2/2 mice [10]. However, the
individual contribution of p16
INK4a remains unknown.
Bone marrow cells give rise to immune cells, which play a crucial
role during the initiation and propagation of type 2 diabetes and
atherosclerosis. A key event in type 2 diabetes and atherosclerosis is
the recruitment of inflammatory cells to, respectively, adipose tissue
(AT) [12] and the neo-intima of large arteries [13]. p16
INK4a is
expressed in macrophages of human atherosclerotic plaques, where
it correlates with the expression of the macrophage marker CD68
and with tumor necrosis factor (TNF) [14]. Recently, we showed
that p16
INK4a-deficiency in murine bone marrow-derived macro-
phages inhibits inflammatory JAK2-STAT1 signaling, promoting
the polarization into alternatively activated (M2) macrophages [15],
which have been shown to protect against the development of
obesity-induced glucose intolerance and insulin resistance [16]. In
addition, p16
INK4a plays a role in T-lymphocytes, an immune cell
type involved in type 2 diabetes [17] and atherosclerosis [13]
development, by inhibiting their activation-induced proliferation
[18] and by inducing apoptosis [19]. Moreover, we have recently
discovered that p16
INK4a expression levels play a role in
determining the inflammatory phenotype of adipose tissue macro-
phages (ATM) [20].
Given the role of immune cell p16
INK4a, given the association of
theCDKN2A locustocardiovasculardisease and type2 diabetesand
given the effects of bone marrow CDKN2A-deficiency on athero-
sclerosis development, we investigated the contribution of bone
marrow p16
INK4a-deficiency to the development of obesity, glucose
intolerance and atherosclerosis in appropriate mouse models.
Materials and Methods
Mice and diets
Low density lipoprotein receptor-deficient (ldlr
2/2) acceptor
mice were house-bred and C57BL/6J acceptor mice were
purchased from Charles River. All protocols were conducted with
the approval of the ethical review boards of the Pasteur Institute,
Lille, France (CEEA 13/2010) and Maastricht University,
Maastricht, The Netherlands (DEC 2007-117). p16
INK4a-deficient
mice on the C57BL/6J background (.97%) were kindly provided
by P. Krimpenfort.
For metabolic experiments, chimeric male C57/BL/6J mice
were given a high fat diet (HFD) containing 20% lard and 35%
sucrose (Ssniff, Germany). For atherosclerosis experiments,
chimeric female ldlr
2/2 mice were given western diet containing
21% milk butter and 0.2% cholesterol (Safe, France).
After the dietary period, blood samples were collected be retro-
orbital puncture and animals were sacrificed by cervical
dislocation and organs were snap frozen for further analysis.
Biochemical analysis
Plasma levels of total cholesterol (TC), triglycerides (TG) and
high density lipoprotein cholesterol (HDL-C) were measured using
commercially available kits (BioMe ´rieux). Non-HDL-cholesterol
(N-HDL-C) was calculated by subtraction of HDL-C from TC.
Alanine aminotransferase (ALAT) (Biolabo), aspartate aminotrans-
ferase (ASAT) (Biolabo), insulin (Mercodia) and free fatty acid
(Diasys) levels were determined according to the manufacturer’s
instructions.
Bone marrow transplantation (BMT)
8 week-old male C57BL/6J or female ldlr
2/2 mice were
lethally irradiated (8 Gy) and tail vein injected the next day with
10
7 bone marrow cells isolated from 8 week-old p16
2/2 or p16
+/+
littermate donor mice. Mice received autoclaved acidified water
(pH=2) supplemented with neomycin 100 mg/L (Cat.N1142,
Sigma-Aldrich) and polymyxin B sulphate 60000 U/L
(Cat.21850029, Invitrogen) 1 week before and 4 weeks after
transplantation. Mice were studied 6 weeks post-transplantation
allowing complete repopulation by the donor bone marrow. To
ensure that donor bone marrow efficiently replaced the resident
blood cell population, DNA was extracted from whole blood with
an Illustra blood kit (GE Healthcare). PCR was performed with
the forward 59-GCA-GTG-TTG-CAG-TTT-GAA-CCC-39 and
reverse 59-TGT-GGC-AAC-TGA-TTC-AGT-TTG-39 primers,
yielding products of different lengths depending on the genotype,
separated on a 1.5% agarose gel and quantified with the Gel Doc
XR system (Bio-Rad). Over 95% of host blood cells were from
donor origin. Flow cytometric analysis of blood cell populations
was performed as described [21].
Isolation of the stromal vascular fraction from white
adipose tissue (WAT)
AT was cut into small pieces, washed with PBS and digested in
Krebs buffer (pH=7.4) containing collagenase (1.5 mg/ml, Roche
Diagnostic) at 37uC during 1 h, filtered through a 200 mm filter
(Spectra Mesh nylon filters; Biovalley) and centrifuged at
1500 rpm for 15 min to separate floating adipocytes. After two
washes of the adipocyte fraction with PBS, adipocytes were
collected and kept at 280uC for DNA and RNA extraction. The
Stromal Vascular cell Fraction (SVF) was pelleted and red blood
cells were lysed with erythrocyte lysis buffer (NH4Cl, 131 mM;
NH4CO3, 9 mM; EDTA, 1 mM; pH 7.4) for 5 min; the
remaining cells were filtered through filter meshes with pore size
of 70 mm (Spectra Mesh nylon filters; Biovalley). SVF was
subjected to Magnetic-Activated Cell Sorting (MACS) in order
to isolate ATM CD11b
+ cells using CD11b-labelled magnetic
beads (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. The CD11b
2 fraction was cultured in Preadipocyte Basal
Medium (PBM, Promocell) for 24 h to eliminate cell types other
than preadipocytes. Only adherent cells were used for RNA and
DNA extraction. RNA extraction was performed using RNeasy
kits (Qiagen) and DNA extraction with Nucleospin Tissue columns
(Marchery-Nagel) according to the manufacturer’s instructions.
PCR was performed as described for blood chimerism.
RNA quantification by real-time PCR
Tissue RNA was isolated using the guanidinium thiocyanate
(GSCN)/phenol/chloroform extraction method and 1 mg mRNA
was reverse transcribed using the SuperScript First-strand
Synthesis System for Reverse transcription (Life Technologies,
Gaithersburg, MD, USA). Reverse transcribed cDNAs were
quantified by SYBR green-based real-time PCR using specific
oligonucleotides on a Mx3000 apparatus (Stratagene, La Jolla,
CA). mRNA levels were normalized to cyclophilin expression as
internal control.
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Blood samples were collected from the tail vein at 0, 5, 15, 30,
60, 90 or 120 min after a bolus glucose (1 g/kg) injection (after fast
6 hours of fasting) and glycemia was measured using a Glucometer
(Accu-Check activeH, Roche Applied Science). To avoid time-
dependent effects, GTT were performed at 2 different time points,
i.e. after 16 and 20 weeks of high fat feeding. To circumvent
influences of glucose injection on hepatic gene expression, animals
Figure 1. Bone marrow p16
INK4a-deficiency does not modulate HFD-induced body weight gain. A. Genotype (arrow shows the p16
2/2
DNA construct) of adipocytes, CD11b
+ cells (macrophages) and preadipocytes isolated from AT of mice transplanted with p16
2/2 bone marrow after
16 weeks of HFD (22 weeks post-transplantation). B. Body weight was monitored of mice transplanted with p16
+/+ (p16
+/+ BMT) (chow n=9, open
circles; HFD n=12, open squares) or p16
2/2 (p16
2/2 BMT) (chow n=8, closed circles; HFD n=12, closed squares) bone marrow and were sacrificed
after 22 weeks of dietary treatment. Body weight (C), inguinal AT (D), epidydimal AT (E) and liver (F) weights were measured. White bars represent
p16
+/+ BMT mice and black bars represent p16
2/2 BMT mice. Statistical differences are indicated * p,0.05 compared to chow fed animals of the same
genotype.
doi:10.1371/journal.pone.0032440.g001
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HFD.
Macrophage cholesterol assays
Bone marrow-derived macrophages (BMDM) were obtained
from femoral and tibial bone marrow suspensions plated at
10610
6 cells in 10 cm plates and differentiated in bone marrow
medium (RPMI 1640 containing Hepes 25 mM supplemented
with 10% low endotoxin fetal bovine serum, 15% L929-
conditioned medium, 2 mM L-glutamine, 1 mM gentamycine).
Cholesterol esterification was assessed by measuring the incorpo-
ration of [14C]-oleate into cholesteryl esters after incubation with
acetylated (Ac) LDL (50 mg/mL) for 24 and 48 hours. After the
cholesterol-loading period, cholesteryl ester formation was mea-
sured as described [22]. Cholesterol efflux to HDL was measured
after macrophage cholesterol-loading with [3H]cholesterol-
AcLDL (50 mg/mL) for 48 h as described [22].
Atherosclerotic Lesion analysis
Mice were euthanized by cervical dislocation and the heart of
each animal was rinsed with PBS and fixed with 4% phosphate-
buffered paraformaldehyde (pH=7.4). Serial 10-mm-thick sections
were cut between the valves and the aortic arch and lipid
deposition was quantitatively analyzed by Oil red-O staining.
Toluidine staining and Sirius red staining were performed and
plaque morphology and stability were scored by a blinded animal
pathologist as described [21]. Immunohistochemical analysis of
TNF and MCP1 was performed using specific antibodies (Santa
Cruz Biotechnology), followed by detection with biotinylated
secondary antibodies and streptavidin-horseradish peroxidase.
Immunostainings were visualized using the DAB substrate-
chromogen system (DAKO Corporation, Carpinteria, Calif).
Images were captured using a JVC 3-charge-coupled device video
camera. Sections were analyzed using the computer-assisted Quips
Image analysis system (Leica Mikroskopic und System GmbH,
Wetzlar, Germany).
Statistical analysis
Groups were compared using 2-tailed non-paired t-tests or 2-
way ANOVA using GraphPad Prism software. In vitro data are
expressed as means 6 SD and in vivo data are expressed as means
6 SEM.
Results
Bone marrow p16
INK4a-deficiency does not affect high fat
diet-induced obesity or glucose intolerance
Since we previously observed that p16
INK4-deficiency modulates
the inflammatory phenotype of murine macrophages [15] and since
p16
INK4a knock-down directs human macrophages toward an
ATM-likephenotype[20],weanalyzed thecontributionofthe bone
marrow p16
INK4a-deficiency to diet-induced adipose tissue devel-
opment and glucose intolerance in mice. C57BL/6 mice were
transplanted with either wild-type (p16
+/+ BMT) or p16
INK4a-
deficient (p16
2/2 BMT) bone marrow. After 6 weeks of recovery,
over 95% of blood cells were from donor origin (data not shown)
and blood immune cell composition was similar between the
genotypes (data not shown). Importantly, after 16 weeks of HFD
feeding, the presence of donor cells in the macrophage (CD11b
+)
fraction of adipose tissue (AT) was over 85% while neither mature
adipocytes,nor preadipocyteswerefromdonororigin(Fig.1A).The
animals were fed a HFD during 22 weeks and body weight and
blood parameters were monitored. Food intake was equal during
the dietary period (data not shown). No difference was observed in
body weight gain between p16
+/+ BMT and p16
2/2 BMT mice
either on normal chow diet or on a HFD (Fig. 1B). At the end of the
dietary period, neither body weight (Fig. 1C), inguinal AT (iAT)
(Fig. 1D), epidydimal AT (eAT) (Fig. 1E) nor liver weight (Fig. 1F)
Table 1. Plasma parameters.
p16
+/+ BMT p16
2/2 BMT
chow HFD chow HFD
Glycemia (mg/dl) 10468 154627*** 103616 140623*
Plasma Insulin (mg/L) 0.860.5 1.5960.8* 0.6660.2 1.6460.7
Plasma FFA (nM) 0.660.2 0.6160.2 0.7560.2 0.9560.6
Plasma AST (UI/L) 30693 2 683 2 653 4 66
Plasma ALT (UI/L) 32613 31662 8 632 9 67
Plasma total Cholesterol (mg/dl) 7766 145633*** 79671 3 4 630***
HDL Cholesterol (mg/dl) 50668 8 623*** 51647 9 621*
non-HDL Cholesterol (mg/dl) 26665 6 616*** 24610 55612***
Triglycerides (mg/dl) 76611 63612 91612 72621
p16
+/+ BMT ldlr
2/2 p16
2/2 BMT ldlr
2/2
chow HFD chow HFD
Plasma total Cholesterol (mg/dl) 242630 11356135*** 238632 10346144***
HDL Cholesterol (mg/dl) 6764 103613*** 63610 107616***
non-HDL Cholesterol (mg/dl) 172621 10376137*** 175631 9276149***
Triglycerides (mg/dl) 124629 3986105*** 124624 400691***
Plasma lipids were measured after 22 weeks standard chow or HFD feeding of male p16
+/+ BMT (chow n=9; HFD n=12) or p16
2/2 BMT (chow n=8; HFD n=12) mice.
Plasma lipid measurements before (chow) and after (9 weeks) the dietary period in p16
+/+ BMT ldlr
2/2 (n=17) or p16
2/2 BMT ldlr
2/2 (n=16) mice. Values are shown 6
standard deviation. Statistical differences are indicated * p,0.05, ** p,0.01, *** p,0.001 compared to chow-fed controls.
doi:10.1371/journal.pone.0032440.t001
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insulin, free fatty acids (FFA), liver enzymes (ALT/AST) and lipids
didnotdifferbetweenp16
+/+BMTand p16
2/2BMTmiceafter22
weeks on chow or on a HFD (Table 1).
No difference in glucose tolerance was observed between p16
+/+
BMTand p16
2/2BMTmiceonchoworaftereither16weeksor20
weeks of HFD (Fig. 2A–D), time points when at least 85% of ATMs
were from donor origin (Fig. 1A). Since p16
INK4a alters macrophage
polarization status [15] and since obesity is associated with a shift
toward classically activated macrophages in AT [23] and in the liver
[24], macrophage polarization markers were measured in these
organs. The gene expression profile of AT from p16
2/2 BMT mice
revealed no difference in the HFD-induced expression (compared to
low fat chow-fed animals as baseline) of either alternatively or
classically activated macrophage markers compared to p16
+/+ BMT
mice (Fig. 3A). Interestingly, hepatic HFD-induced expression
(compared to low fat chow-fed animals as baseline) of the alternative
marker IL10 was higher and the induction of Chi3l3 tended to be
higher (p=0.065) in p16
2/2 BMT mice. Moreover, Mgl2 was
induced in p16
2/2 BMT mice but not in p16
+/+ BMT mice
(Fig. 3B). Contrary, the induction of the classical marker NOS2 was
completely ablated compared to p16
+/+ BMT mice (Fig. 3B).
Collectively, these data show that bone marrow p16
INK4a-
deficiency does not modulate HFD-induced obesity or glucose
metabolism.
Bone marrow p16
INK4a-deficiency does not influence
atherosclerosis size or lesion composition in
hyperlipidemic ldlr
2/2 mice
Since bone marrow CDKN2A-deficiency in ldlr
2/2 mice
increases atherosclerosis development [10], we investigated the
specific contribution of bone marrow p16
INK4a-deficiency to
atherosclerosis development. Atherosclerosis-prone ldlr
2/2 mice
were transplanted with either wild-type (p16
+/+ BMT ldlr
2/2)o r
p16
INK4a-deficient (p16
2/2 BMT ldlr
2/2) bone marrow [25].
The animals were fed a western diet during 9 weeks and
physiological parameters and atherosclerosis development were
monitored, a time point comparable to the one where the effects of
bone marrow CDKN2A-deficiency were observed [10].
Blood cell replacement was higher than 95% and no differences
were observed in blood monocyte, neutrophil, B-lymphocyte or T-
lymphocyte composition (data not shown). No differences were
observed in plasma TC, HDL-C, non-HDL-C or TG between
p16
+/+ BMT ldlr
2/2 and p16
2/2 BMT ldlr
2/2 mice (Table 1).
Intracellular cholesterol metabolism in macrophages is a
determining factor of plaque initiation and formation [26].
Therefore, since IFNc influences foam cell formation by
diminishing cholesterol efflux [27] and since p16
INK4a-deficiency
alters IFNc-induced signaling [15], uptake and efflux of cholesterol
in wild type and in p16
INK4a-deficient macrophages were
compared. As shown in Fig. 4, cholesterol uptake as well as efflux
Figure 2. Bone marrow p16
INK4a-deficiency does not affect HFD-induced glucose intolerance. Glucose tolerance tests (GTT) were
performed after 16 and 20 weeks of HFD feeding of male p16
+/+ BMT (chow n=9, open circles; HFD n=12, open squares) or p16
2/2 BMT (chow n=8,
closed circles; HFD n=12, closed squares) mice. Blood glucose values were monitored after 1 g/kg glucose injection (A. 16 weeks; B. 20 weeks) and
areas under the curve were calculated (C. 16 weeks; D. 20 weeks). White bars represent p16
+/+ BMT mice and black bars represent p16
2/2 BMT mice.
Statistical differences are indicated * p,0.05 compared to chow fed animals of the same genotype.
doi:10.1371/journal.pone.0032440.g002
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INK4a-deficient BMDM was equal compared to
their wild type counterparts.
After 9 weeks of western diet, no differences were observed in
mean plaque size (Fig. 5A) or in plaque size distribution (Fig. 5B).
Moreover, neither plaque Sirius Red-positive collagen content
(Fig. 5C), nor the inflammatory phenotype, illustrated by
immunohistochemical staining of plaque MCP1 (Fig. 5D) and
TNF (Fig. 5E), were affected. Additionally, blind scoring of
toluidine-stained sections by an animal pathologist showed no
changes in plaque necrosis, foam cell content, monocyte adhesion,
neutrophil content or adventitial influx (data not shown).
Collectively, these data show that bone marrow p16
INK4a-
deficiency does not alter atherosclerosis development or plaque
phenotype in ldlr
2/2 mice.
Discussion
Genetic susceptibility contributes significantly to cardiovascular
disease [28,29] and type 2 diabetes [30] risk. Therefore, the
identification of genes and mechanisms behind newly found
genetic associations, such as for p16
INK4a, will provide new insights
and therapeutic possibilities for targeting atherosclerosis and type
2 diabetes. The locus coding for p16
INK4a has been linked to the
risk for type 2 diabetes [1] and atherosclerotic vascular disease [2]
and bone marrow-specific heterozygous deletion of CDKN2A
(including p16
INK4a and p19
ARF, the murine variant of p14
ARF)i s
required and sufficient to accelerate atherosclerosis formation
[10]. Therefore, we investigated the specific role of bone marrow
p16
INK4a on obesity, glucose tolerance and atherosclerosis
Figure 3. Bone marrow p16
INK4a-deficiency alters hepatic, but not AT HFD-induced gene expression. p16
+/+ BMT (chow n=9; HFD
n=12) or p16
2/2 BMT (chow n=8; HFD n=12) mice were sacrificed after 22 weeks of dietary treatment. Epidydimal AT (A) and liver (B) mRNA were
isolated and inflammatory genes were measured by qPCR. Data are expressed relative to low fat chow-fed controls of the same genotype (set at 1,
dotted line). White bars represent p16
+/+ BMT mice and black bars represent p16
2/2 BMT mice. Statistical differences are indicated * p,0.05,
** p,0.01, *** p,0.001 compared to chow-fed controls; $$$ p,0.001 compared between the HFD-fed groups.
doi:10.1371/journal.pone.0032440.g003
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INK4a-deficiency
does not alter susceptibility to high fat diet-induced obesity and
glucose intolerance or to western diet-induced atherosclerosis
development.
Blood cell replacement was efficient as soon as 6 weeks post-
transplantation, excluding an ineffective repopulation of the host
bone marrow to have influenced our results. Since aging influences
p16
INK4a expression [31], it is important to note that we used bone
marrow from young mice of the same age to avoid age-related
effects. Additionally, ATMs were efficiently replaced at the
moment of metabolic testing. The observation that p16
INK4a-
deficiency was only found in CD11b
+ cells but not in pre-
adipocytes or in adipocytes contributes to the debate about a
possible bone marrow origin of (pre)-adipocytes [32], arguing
against such an origin of these cells.
Macrophage inflammatory status is an important determinant
of the progression of both atherosclerosis and obesity-induced
glucose intolerance. For example, inhibition of IFNc-induced
STAT1 signaling protects against atherosclerosis development
[33] and IFNc is associated with the development of AT in obese
patients [34] and diminishes insulin signaling in human adipocytes
[35]. We recently discovered that macrophage p16
INK4a-deficien-
cy inhibits pro-inflammatory JAK2-STAT1 signaling [15].
However, bone marrow p16
INK4a-deficiency appears insufficient
to affect atherosclerosis progression, obesity development or
glucose homeostasis in mice. Moreover, despite the effects of
p16
INK4a-deficiency on macrophage polarization status [15],
p16
INK4a-deficiency in bone marrow cells did not influence the
inflammatory signature in AT. In the liver, however, we observed
higher induction of some alternative activation markers and NOS2
induction was completely inhibited, providing evidence that the
anti-inflammatory phenotype of p16
INK4a-deficient macrophages
is, albeit modestly, observed in vivo, in line with our previous
observations [15].
Our results may reflect that the association of the CDKN2A/B
locus with type 2 diabetes and cardiovascular disease depends on
gene products other than p16
INK4a encoded by this high risk
genomic region, such as p19
ARF or p15
INK4b. For example, whole-
body deficiency of the other gene product of CDKN2A, i.e. p19
ARF,
aggravates atherosclerosis development in apoe
2/2 mice, although
the exact mechanisms and cell types involved in vivo remained
elusive [11]. Combined with the recently published data showing
that bone marrow-specific deletion of the complete CDKN2A locus
promotes atherosclerosis development [10], our results exclude the
involvement of solely p16
INK4a. Experiments using p19
ARF bone
marrow will show whether p19
ARF alone or the combined deletion
of both CDKN2A gene products in bone marrow-derived cells is
required for influencing atherosclerosis progression. However, ithas
to be taken into account that there is only 50% homology between
the human 9p21 and the corresponding murine genomic region
[36]. We therefore should be careful when trying to extrapolate the
findings of murine studies to humans.
Alternatively, it is possible that p16
INK4a is involved in the
development of type 2 diabetes and atherosclerosis by acting in
other cell types. For example, the CDK4-pRB-E2F1 pathway,
which is inhibited by p16
INK4a, has been shown to control insulin
secretion in b-cells [37]. Furthermore, a recent report has shown
that bone marrow over-expression of p16
INK4a promotes a
prothrombotic phenotype in mice [38], indicating that the link
between the CDKN2A locus and cardiovascular disease may be
primarily related to occlusive vascular events, a parameter that
was not investigated in this study. In parallel, the CDKN2A/B
locus has been strongly associated with coronary artery calcifica-
tion [39], which was not investigated in this study. Finally,
p16
INK4a is also expressed by smooth muscle cells (SMC) and
vascular SMC proliferation is an important event during
atherosclerosis and vascular occlusion [40]. We have previously
shown that p16
INK4a plays a role in this process [41], making it
feasible that p16
INK4a contributes to cardiovascular disease via this
mechanism. Since bone marrow p16
INK4a-deficiency did not affect
collagen deposition and since we did not observe any differences
with respect to changes in the media of the vessel wall (data not
shown), the effects of p16
INK4a on vascular remodeling during
atherosclerosis and restenosis appear independent of immune cells
or other bone marrow-derived cells. Together with the fact that
deleting the mouse region orthologous to the human 9p21 risk
interval results in increased SMC proliferation in vitro [9], these
observations point to a major role of p16
INK4a in SMC.
In conclusion, our results argue against a major role for
p16
INK4a in bone marrow cells in the development of obesity,
Figure 4. Bone marrow p16
INK4a-deficiency does not influence macrophage cholesterol metabolism. BMDM from p16
+/+ and p16
2/2
mice were cultured and cholesterol uptake (A) and efflux to HDL (B) were measured. White bars represent p16
+/+ BMDM and black bars represent
p16
2/2 BMDM.
doi:10.1371/journal.pone.0032440.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32440glucose intolerance or atherosclerosis. These observations shed
light on the found linkage disequilibrium found in GWAS between
these conditions and the CDKN2A/B region. The effects of
p16
INK4a-deficiency on inflammatory phenotype thus appear
insufficient to affect atherosclerosis or the development of obesity
and glucose intolerance suggesting the involvement of other cell
types, other gene products or combinations thereof in the
CDKN2A/B genomic region.
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